Results 161 to 170 of about 5,199,515 (344)
Tumor mutational burden as a determinant of metastatic dissemination patterns
Molecular Oncology, EarlyView.This study performed a comprehensive analysis of genomic data to elucidate whether metastasis in certain organs share genetic characteristics regardless of cancer type. No robust mutational patterns were identified across different metastatic locations and cancer types.
Eduardo Candeal +4 more
wiley +1 more source
Trial-by-trial learning of successor representations in human behavior. [PDF]
PLoS Comput BiolKahn AE, Bassett DS, Daw ND.
europepmc +1 more source
Characterizing the role of human behavior in the effectiveness of contact-tracing applications. [PDF]
Front Public Health, 2023 Fosch A, Aleta A, Moreno Y.
europepmc +1 more source
Molecular Oncology, EarlyView.Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat +8 more
wiley +1 more source
AI assessment changes human behavior. [PDF]
Proc Natl Acad Sci U S AGoergen J, de Bellis E, Klesse AK.
europepmc +1 more source
Nanoindentation creep behavior of human enamel [PDF]
, 2008 Lihong He, Michael V. Swain
openalex +1 more source
The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity
Molecular Oncology, EarlyView.Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli +7 more
wiley +1 more source